Clinical Trials Directory

Trials / Completed

CompletedNCT02678208

The Effect of Tranexamic Acid on Uterine Blood Flow After Vaginal Delivery

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
200 (actual)
Sponsor
Assiut University · Academic / Other
Sex
Female
Age
20 Years – 40 Years
Healthy volunteers
Not accepted

Summary

Postpartum hemorrhage is the most common cause of maternal death across the world, responsible for more than 25% of maternal deaths annually. Although effective tools for prevention and treatment of are available, most are not feasible or practical for use in the developing world where many births still occur at home with untrained birth attendants . primary postpartum hemorrhage is excessive bleeding from or in the genital tract within 24 hours of delivery of the fetus which affects the general condition. Postpartum hemorrhage is responsible for around 25% of maternal mortality worldwide , reaching as high as 60% in some countries. Postpartum hemorrhage can also be a cause of long-term severe morbidity, and approximately 12% of women who survive postpartum hemorrhagewill have severe anemia. Tranexamic acid is an antifibrinolytic compound which is a potent competitive inhibitor of the activation of plasminogen to plasmin. At much higher concentrations it is a non-competitive inhibitor of plasmin. The inhibitory effect of tranexamic acid in plasminogen activation by urokinase has been reported to be 6-100 times and by streptokinase 6-40 times greater than that of aminocaproic acid.

Conditions

Interventions

TypeNameDescription
DRUGTranexamic Acid
DRUG5% glucose

Timeline

Start date
2015-02-01
Primary completion
2015-07-01
Completion
2015-08-01
First posted
2016-02-09
Last updated
2016-03-01

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT02678208. Inclusion in this directory is not an endorsement.